Analyst Confident In NewAmsterdam Pharma's Cholesterol Drug Despite Mixed Reactions To Study Results (CORRECTED)
Portfolio Pulse from Vandana Singh
NewAmsterdam Pharma (NASDAQ:NAMS) released positive topline data from its Phase 3 BROOKLYN trial for obicetrapib, showing significant LDL-C reduction in HeFH patients. Despite meeting primary endpoints, the stock experienced volatility, closing 8.35% lower. Analyst William Blair remains confident in the drug's potential, reiterating an Outperform rating.
July 30, 2024 | 7:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NewAmsterdam Pharma's Phase 3 BROOKLYN trial for obicetrapib showed significant LDL-C reduction, but the stock closed 8.35% lower due to mixed reactions. Analyst William Blair remains confident, reiterating an Outperform rating.
The Phase 3 trial results were positive, showing significant LDL-C reduction, which is crucial for HeFH patients. Despite the stock's initial drop, the analyst's confidence and Outperform rating suggest a potential rebound.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100